

---

# Final permission received, BSG005 to reach patients

Carlsquare Equity Research comments on Biosergen's recently received import license and the incipient phase Ib study.

[Read the full comment here.](#)

## About Carlsquare

---

Carlsquare is a global research firm and financial advisor, focusing on M&A, Equity Research and Growth Equity. Carlsquare has 150 employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team has extensive experience about the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. [Read more](#)

### Contact

MARKUS AUGUSTSSON  
Head of Equity Research  
[markus.augustsson@carlsquare.com](mailto:markus.augustsson@carlsquare.com)  
+46 (0)76 235 03 20

### Contacts

---

#### MARKUS AUGUSTSSON

Head of Equity Research  
[markus.augustsson@carlsquare.com](mailto:markus.augustsson@carlsquare.com)  
+46 (0)76 235 03 20

#### NIKLAS ELMHAMMER

Senior Equity Analyst  
[niklas.elmhammer@carlsquare.com](mailto:niklas.elmhammer@carlsquare.com)  
+46 (0)70 898 39 59

### Attachments

---

[Final permission received, BSG005 to reach patients](#)